{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T09:10:46Z","timestamp":1775466646593,"version":"3.50.1"},"reference-count":38,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T00:00:00Z","timestamp":1499644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Haemate\u2010P\/Humate\u2010P (Humate\u2010P) is a pasteurized human plasma\u2010derived concentrate containing both Factor VIII and von Willebrand factor for treatment of hemophilia A and von Willebrand disease (VWD).<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>We analyzed the safety of Humate\u2010P based on more than 33 years of postmarketing pharmacovigilance data, representing an estimated exposure of approximately 25,000 patient\u2010years. The analysis comprises reports of potential adverse drug reactions (ADRs) from all sources, reported as part of routine pharmacovigilance at CSL Behring. ADRs considered clinically relevant or potential risks of Humate\u2010P were identified based on defined and standardized Medical Dictionary for Regulatory Activities queries. Recognizing the limitations of spontaneous reporting, we also reviewed the literature, including clinical trials with mandatory reporting.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>From 1982 to 2015, a total of 670 postmarketing cases had been reported via pharmacovigilance, for an overall reporting rate of approximately one ADR per 3900 administered standard doses. Of these cases, 343 involved ADRs considered clinically relevant risks (33 thromboembolic complications, 97 inhibitor formation, 110 hypersensitivity or allergic reactions) or potential risks (103 suspected virus transmissions) for Humate\u2010P. Most thromboembolic complications occurred in patients undergoing surgery or with other known risk factors. Inhibitor formation occurred mostly in patients with hemophilia A (24 cases were high titer). Most patients with hypersensitivity or allergic reactions had VWD. None of the reported suspected virus transmission cases were confirmed to be associated with Humate\u2010P. Reported results of company\u2010sponsored studies showed a low incidence of adverse events possibly or probably related to Humate\u2010P.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>More than 33 years of pharmacovigilance data continue to support the safety of Humate\u2010P.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.14241","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T06:08:47Z","timestamp":1499666927000},"page":"2390-2403","source":"Crossref","is-referenced-by-count":18,"title":["Safety of a pasteurized plasma\u2010derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data"],"prefix":"10.1111","volume":"57","author":[{"given":"Peter","family":"Kouides","sequence":"first","affiliation":[{"name":"Department of Medicine University of Rochester School of Medicine Rochester New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Wawra\u2010Hehenberger","sequence":"additional","affiliation":[{"name":"CSL Behring Marburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sajan","sequence":"additional","affiliation":[{"name":"CSL Behring King of Prussia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Mead","sequence":"additional","affiliation":[{"name":"CSL Behring King of Prussia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toby","family":"Simon","sequence":"additional","affiliation":[{"name":"CSL Behring King of Prussia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1601561"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629873"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39111160.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(09)70152-5"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-949668"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00893.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613747"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3033.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740330902719481"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00816.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1612977"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.12.017"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00809.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613227"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/beha.2001.0139"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890701513738"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-0331-2_7"},{"key":"e_1_2_8_19_1","first-page":"717","volume-title":"Principles of transfusion medicine","author":"Gunter KC","year":"1996"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02916.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12075"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613225"},{"issue":"2","key":"e_1_2_8_23_1","first-page":"1","article-title":"Case study of two consanguineous brothers with type 3 von Willebrand disease (VWD), inhibitors and anaphylactoid reaction to VWF [abstract OR022]","volume":"13","author":"Dangelo L","year":"2015","journal-title":"J Thromb Haemost"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-09-0616"},{"issue":"2","key":"e_1_2_8_25_1","first-page":"1","article-title":"Clinical and laboratory detection of transient neutralizing antibodies in severe von Willebrand disease on long term prophylaxis [abstract PO646\u2010TUE]","volume":"13","author":"Sanchez\u2010Luceros A","year":"2015","journal-title":"J Thromb Haemost"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01852.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02588.x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02534.x"},{"issue":"2","key":"e_1_2_8_29_1","first-page":"290","article-title":"Haemate P for the treatment of vWD and haemophilia A: new results of a pharmacovigilance project [abstract PB 3.37\u20104]","volume":"11","author":"Krause M","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"2","key":"e_1_2_8_30_1","first-page":"1","article-title":"Plasma\u2010derived, purified, pasteurised von Willebrand factor\/factor VIII concentrate in the treatment of patients with von Willebrand disease and haemophilia A: update of a long\u2010term observational study [abstract PO647\u2010MON]","volume":"13","author":"Wermes C","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"2","key":"e_1_2_8_31_1","first-page":"1","article-title":"Immune tolerance induction with Haemate P in hemophilia A: experience from a single center [abstract PO263\u2010MON]","volume":"13","author":"Knofler R","year":"2015","journal-title":"J Thromb Haemost"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098613490780"},{"key":"e_1_2_8_34_1","first-page":"105","article-title":"Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end\u2010stage renal failure patients","volume":"5","author":"Jacob D","year":"2013","journal-title":"Drug Healthc Patient Saf"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90166-3"},{"key":"e_1_2_8_36_1","first-page":"1","article-title":"Elevated plasma factor VIII levels\u2014a novel risk factor for venous thromboembolism","volume":"47","author":"O'Donnell J","year":"2001","journal-title":"Clin Lab"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12498"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516437"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-06-0514"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.14241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.14241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.14241","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.14241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T16:01:12Z","timestamp":1694016072000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.14241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1111\/trf.14241"],"URL":"https:\/\/doi.org\/10.1111\/trf.14241","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,10]]}}}